1. Home
  2. TEVA

as 05-20-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Founded: 1901 Country:
Israel
Israel
Employees: N/A City: TEL AVIV
Market Cap: 18.5B IPO Year: N/A
Target Price: $14.22 AVG Volume (30 days): 10.1M
Analyst Decision: Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.44 EPS Growth: N/A
52 Week Low/High: $7.09 - $17.13 Next Earning Date: 05-08-2024
Revenue: $16,004,000,000 Revenue Growth: 7.22%
Revenue Growth (this year): 1.39% Revenue Growth (next year): 2.73%

Share on Social Networks: